ArticleEuropean radiology2026
Long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for refractory hepatic encephalopathy.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emergency Plug-assisted Retrograde Transvenous Obliteration Using an Optimo 9-Fr Balloon Guiding Catheter: A Case Report.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for the treatment of medically refractory hepatic encephalopathy (HE). MATERIALS AND
methodsFifty-eight patients with cirrhosis who presented with one or more types of large portosystemic shunt (PSS) between April 2009 and March 2023 and had a history of at least two episodes of recurrent HE in the preceding 6 months were included in this retrospective study. Clinical follow-up included venous ammonia and West Haven (WH) score assessment. Technical and long-term outcomes were reviewed and analyzed.
resultsThe technical success rate was 98.3% (57 of 58 patients). The mean procedure time was 29 min (range, 9-114 min). The immediate clinical success rate was 98.3%. The median WH score improved significantly from 2 (range, 1-3) pre-PARTO to 0 (range, 0-1) post-PARTO (p < 0.001). The mean serum ammonia level, which was 82.4 µmol/dL ± 46 before PARTO, decreased significantly to 23.7 µmol/dL ± 17 within 1 week after PARTO (p < 0.001). Long-term follow-up data were available for only 48 patients because of early death (n = 2), follow-up loss (n = 2), or liver transplantation (n = 5). The obliteration rate of PSS was 100%. Nine (18.8%) patients experienced recurrence of HE at a mean of 19.6 months (range 1.5-32.8 months). The cumulative 1-, 2-, 3-, 5-, and 10-year recurrence rates of HE were 6.4%, 14.9%, 27.5%, 27.5%, and 27.5%, respectively. The median transplantation-free survival time was 45.7 months (95% confidence interval, 25-66.5 months).
conclusionHigh clinical success rate and low recurrence rate of HE during the long-term follow-up period suggest that PARTO is an effective treatment for refractory HE due to PSS in patients with liver cirrhosis. KEY POINTS: Question The efficacy and long-term outcomes of plug-assisted retrograde transvenous obliteration for patients with hepatic encephalopathy have not yet been strictly determined. Findings The clinical symptoms of hepatic encephalopathy completely resolved in 57 (98.3%) of 58 patients within 2 days after plug-assisted retrograde transvenous obliteration. Clinical relevance Long-term outcomes suggest that plug-assisted retrograde transvenous obliteration is an effective treatment for refractory hepatic encephalopathy due to portosystemic shunt in patients with liver cirrhosis.
Indexed as
Identifiers
40670766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.